Tumor Angiogenesis Therapy Using Targeted Delivery of Paclitaxel to the Vasculature of Breast Cancer Metastases

Figure 3

Cytotoxic activity of PTX-FFRck-fVIIa against MDA-MB-231 breast cancer cells and Tu212 SCC cells in vitro. PTX and PTX-FFRck-fVIIa require over 1,000 nM to kill MDA-MB-231 cells but between 10 and 100 nM to kill Tu212 cells 100%, respectively.

(a)

(b)